The food signal and the pill signal point opposite ways. Early cohorts found people eating the most vitamin E had 30–40% less heart disease 1. But those people also ate more nuts, greens, and unrefined oils, smoked less, and earned more. The pill stripped all that out and kept one molecule.
Isolated, that molecule did nothing good and some harm. Prostate cancer rose 17% in healthy men on 400 IU/day 2. Pooled trials show all-cause mortality creeping up above 400 IU/day 3. Supplementation cut clotting strokes but raised the bleeding kind by 22% — net-zero on stroke, worse on the type that kills faster 4.
Get it from a plate, not a bottle. The daily target is 15 mg of α-tocopherol, and food clears it without effort.
Real deficiency is rare: under 1% of US adults fall below the clinical cutoff 5. If you eat any fat at all, you almost certainly have enough 6.
Three narrow exceptions, all doctor-run. A hepatologist may put a non-diabetic with biopsy-proven fatty-liver disease on 800 IU/day of natural d-α-tocopherol 7. A neurologist may use 2,000 IU/day off-label in mild-to-moderate Alzheimer's to slow the loss of daily-living skills 8. An ophthalmologist prescribes the AREDS2 eye formula, which contains 400 IU, to slow one stage of macular degeneration 9. Outside those rooms, the bottle stays on the shelf.
The fine print — when to skip it, and what people get wrong
On warfarin, a DOAC, or daily aspirin or clopidogrel: do not add a vitamin E pill — it thins blood on top of your medication 4. Stop supplements two weeks before any surgery or dental procedure.
"It's heart-healthy" is outdated; guidelines dropped it after the trials came in 10. "Higher doses are stronger" is backwards; harm bends up around 400 IU/day. "Rub it on scars" failed in controlled trials and gives some people a rash.
- 1Rimm et al. (1993). Vitamin E consumption and the risk of coronary heart disease in men. New England Journal of Medicine. link
- 2Klein et al. (2011). Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. link
- 3Miller et al. (2005). Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality. Annals of Internal Medicine. link
- 4Schürks et al. (2010). Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ. link
- 5McBurney et al. (2015). Suboptimal serum α-tocopherol concentrations observed among younger adults and those depending exclusively upon food sources, NHANES 2003-2006. PLoS ONE. link
- 6NIH Office of Dietary Supplements (2021). Vitamin E — Health Professional Fact Sheet. link
- 7Sanyal et al. (2010). Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS). New England Journal of Medicine. link
- 8Dysken et al. (2014). Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. link
- 9Age-Related Eye Disease Study 2 Research Group (2013). Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. link
- 10Lonn et al. (2005). Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial (HOPE-TOO). JAMA. link
დაკავშირებული სახელმძღვანელოში (7)
- — Vitamin E is one of the few supervised treatments with real evidence in biopsy-proven fatty-liver disease.
- — Vitamin E is the long-standing cheap option for MASH; resmetirom is the new prescription for when more is needed.
- — Among the older drug-adjacent options in dementia, high-dose vitamin E has a small evidence base at one stage.
- — The AREDS eye formula pairs lutein and zeaxanthin with vitamin E and zinc; vitamin E only clearly helps the eye in this specific combination.
- — An adjacent topic in the handbook.
- — Selenium and vitamin E were tested together as antioxidants in SELECT — they guard overlapping pathways.
- — An adjacent topic in the handbook.
Vitamin E (tocopherols and tocotrienols)
Dietary RDA is met by a handful of nuts or a tablespoon of vegetable oil — effectively free. Supplements run $10–30/year at typical doses; the AREDS2 formula and NASH dosing are similarly inexpensive. Specialty mixed-tocopherol products run higher but are not indicated.
Eating nuts/seeds/oils for dietary adequacy is trivial. Daily pill-taking is also trivial. The harder lift is the negative — knowing not to take 400+ IU/day, and stopping vitamin E ≥2 weeks before surgery or with anticoagulants.
Five large primary-prevention RCTs (ATBC, HOPE-TOO, WHS, PHS II, SELECT) totaling >120,000 randomized participants; Miller 2005 dose-response meta-analysis; Schürks 2010 stroke-subtype meta-analysis; PIVENS NASH trial supporting therapeutic use. Evidence base is unusually strong for both the negative supplementation conclusions and the narrow positive therapeutic indications.
Mechanistic photoprotection in topical formulations (especially combined with vitamin C ± ferulic acid) is real, but evidence that food-level vitamin E intake or oral supplementation produces visible long-term skin or hair benefits is thin and uncontrolled. Oral 400 IU AREDS2 dosing was not tied to skin endpoints. Minor contribution at most.
In iatrogenically untreated populations (NASH per Sanyal 2010, AVED, abetalipoproteinemia, premature infants) supplementation produces clear functional improvement; in the healthy adult who is the typical reader, dietary repletion produces no felt change because clinical deficiency is <1%.
Vitamin E is an essential nutrient — dietary adequacy supports normal lipid-membrane integrity and is required for life. But the supplementation longevity case has been disconfirmed: Miller 2005 meta-analysis shows ≥400 IU/day raises all-cause mortality; HOPE-TOO, WHS, SELECT, PHS II show no mortality benefit. The +1 reflects dietary adequacy as a baseline requirement, not a supplementation win.
TEAM-AD (Dysken 2014) showed 2,000 IU/day delays ADCS-ADL functional decline in mild-to-moderate AD by ~6 months. This is a clinician-supervised therapeutic use in an already-impaired population, not a cognitive-enhancement effect in healthy adults. Score reflects the narrow therapeutic signal.